<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0012">
 <label>12</label>
 <mixed-citation publication-type="other" id="othref0003">Substance Abuse and Mental Health Services Administration (SAMHSA). FAQs: provision of methadone and buprenorphine for the treatment of opioid use disorder in the COVID-19 emergency. Rockville, MD: Substance Abuse and Mental Health Services Administration. 
  <ext-link ext-link-type="uri" xlink:href="http://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf" id="interref0010" xmlns:xlink="http://www.w3.org/1999/xlink">www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf</ext-link>. Updated April 21, 2020. Accessed March 27, 2020.
 </mixed-citation>
</ref>
